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Structured Summary 
Background: In the primary week-48 analyses of two phase 3 studies, coformulated 
bictegravir, emtricitabine, and tenofovir alafenamide was noninferior to a dolutegravir-containing 
regimen in treatment-naïve people with HIV. We report week-144 efficacy and safety results 
from these studies. 
Methods: We conducted two double-blind, active-controlled studies of bictegravir, emtricitabine, 
and tenofovir alafenamide (now in open-label extension phase). Study 1489 randomized (1:1) 
HLA-B*5701-negative adults without hepatitis B coinfection to receive coformulated bictegravir 
50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or coformulated dolutegravir 50 
mg, abacavir 600 mg, and lamivudine 300 mg. Study 1490 randomized (1:1) adults to 
bictegravir, emtricitabine, and tenofovir alafenamide or dolutegravir 50 mg given with 
coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg. We previously reported 
noninferiority at the primary endpoint (proportion with plasma HIV-1 RNA <50 copies per mL at 
week 48 by U.S. Food and Drug Administration Snapshot algorithm); the week-144 secondary 
outcome was analysed in the same manner. These studies were registered with 
ClinicalTrials.gov (NCT02607930 and NCT02607956). 
Findings: 629 participants were randomised and treated in Study 1489 and, 645 participants 
were randomised and treated in Study 1490. At week 144, bictegravir, emtricitabine, and 
tenofovir alafenamide remained noninferior to both dolutegravir-containing regimens for 
efficacy. In Study 1489, the proportion with plasma HIV-1 RNA <50 copies per mL was 81·5% 
(256 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 84·1% (265 
of 315) in the dolutegravir, abacavir, and lamivudine group (difference −2·6%; 95% CI −8·5% to 
3·4%). In Study 1490, the proportion with plasma HIV-1 RNA <50 copies per mL was 81·9% 
(262 of 320 participants) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 
84·0% (273 of 325) in the dolutegravir plus emtricitabine and tenofovir alafenamide group 
(difference −1·9%, 95% CI: −7·8% to 3·9%). In both studies, no participant had treatment-
emergent resistance to study drugs through week 144. All treatment regimens were well 
tolerated  with additional exposure. Adverse events that led to study drug discontinuation were 
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reported for no participants in the bictegravir, emtricitabine, and tenofovir alafenamide vs five of 
315 (2%) in the dolutegravir, abacavir, and lamivudine group (Study 1489) and six of 320 (2%) 
in the bictegravir, emtricitabine, and tenofovir alafenamide vs 6 of 325 (2%) in the dolutegravir 
plus emtricitabine and tenofovir alafenamide group (Study 1490). In Study 1489 (bictegravir, 
emtricitabine, and tenofovir alafenamide vs dolutegravir, abacavir, and lamivudine), statistically 
significant differences were observed in median changes from baseline in fasting total 
cholesterol (14 mg/dL vs 10 mg/dL, p=0.034), direct LDL (21 mg/dL vs 14 mg/dL, p=0·004), and 
total cholesterol to HDL ratio (-0.1 vs -0.3, p=0.007) at week 144; no differences were observed 
for bictegravir, emtricitabine, and tenofovir alafenamide vs dolutegravir, emtricitabine and 
tenofovir alafenamide groups in Study 1490. Weight gain was seen across all treatment groups 
in both studies with no differences in median changes from baseline in weight at week 144 for 
either study.  
Interpretation: These long-term data support bictegravir, emtricitabine, and tenofovir 
alafenamide as safe, well tolerated, and durable treatment for people with HIV, with no 
emergent resistance. 
Funding: Gilead Sciences, Inc. 
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Research in Context 
Evidence before this study 
Data with bictegravir regimens for HIV treatment extends to a maximum follow up time of 96 
weeks. We searched PubMed for randomised clinical trials of bictegravir in people with HIV, 
with title and/or abstract search terms of “bictegravir” and “randomised” or “randomized”. We 
used internet search engines to identify governmental, non-governmental, and professional 
medical society practice guidelines relevant to bictegravir. Searches were limited to English 
language publications between January 1, 1997 and November 1, 2019. Our search yielded 14 
publications, of which we excluded nine as they reported results from switch studies in 
virologically suppressed adults with HIV, meta- and/or systemic analyses, phase 1, or patent-
reported outcome results. The remaining five reports summarised week-48 or -96 outcomes 
from three phase 2 and phase 3 studies of bictegravir, emtricitabine, and tenofovir alafenamide 
in treatment-naïve adults. Across these reports, bictegravir, emtricitabine, and tenofovir 
alafenamide was noninferior to standard-of-care regimens, including those containing 
dolutegravir. Bictegravir, emtricitabine, and tenofovir alafenamide had a similar renal, bone, and 
lipid safety profile relative to the comparators. Bictegravir, emtricitabine, and tenofovir 
alafenamide became a guidelines-recommended regimen for initial treatment of adults with HIV 
based on week-48 data and there remained a need for longer-term data to inform clinical care. 
Added value of this study 
The current randomised, blinded phase 3 studies provide evidence of the long-term (week 144) 
safety and efficacy of bictegravir, emtricitabine and tenofovir alafenamide. Compared with other 
guidelines-recommended treatment regimens (dolutegravir, abacavir, and lamivudine; and 
dolutegravir plus coformulated emtricitabine and tenofovir alafenamide), coformulated 
bictegravir, emtricitabine and tenofovir alafenamide demonstrated noninferior efficacy at week 
144. No participants on any regimen failed with emergent resistance, further demonstrating the 
high barrier to resistance of the study regimens. There was less nausea and fewer drug-related 
adverse effects in those treated with coformulated bictegravir, emtricitabine and tenofovir 
alafenamide compared with those who received dolutegravir, abacavir, and lamivudine. Bone 
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mineral density, glomerular filtration rate, and biomarkers of renal tubular function were similar 
between bictegravir, emtricitabine, and tenofovir alafenamide and dolutegravir, abacavir, and 
lamivudine. 
These studies provide evidence of the durable efficacy, continued tolerability, and no treatment-
emergent resistance for participants taking bictegravir, emtricitabine, and tenofovir alafenamide. 
Implications of all the available evidence 
Data from these current analyses confirm findings from week-48 and -96 reports of randomised 
studies comparing bictegravir, emtricitabine, and tenofovir alafenamide with standard-of-care 
regimens, including those containing dolutegravir. Coformulated bictegravir, emtricitabine, and 
tenofovir alafenamide can be administered once daily, does not require HLA B*5701 testing, 
and provides guideline-recommended therapy for people with HIV and with HIV/hepatitis B virus 
coinfection. Together these studies provide long-term efficacy and safety data to guide 
treatment decisions for people with HIV. 
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Main Text 
Introduction 
Integrase strand transfer inhibitors (INSTIs) anchor HIV treatment worldwide. Treatment 
regimens containing an INSTI and two nucleoside reverse transcriptase inhibitors (NRTIs) 
comprise most European, United States, and WHO guidelines-preferred regimens for the initial 
treatment of HIV.1-4 Bictegravir is the most recent addition to the INSTI class and was compared 
to dolutegravir for initial treatment of HIV as a part of a complete 3-drug regimen in two different 
phase 3 randomised, double-blind, active-controlled trials. Bictegravir, coformulated with 
emtricitabine and tenofovir alafenamide, was compared to coformulated dolutegravir, abacavir, 
and lamivudine in Study 1489 and to dolutegravir plus emtricitabine and tenofovir alafenamide 
in Study 1490. All treatments had high efficacy; the bictegravir regimen was noninferior to either 
dolutegravir-containing regimen through 96 weeks. In Study 1489 where the NRTIs also differed 
between treatment arms, bictegravir, emtricitabine, and tenofovir alafenamide had similar bone 
and renal safety compared to dolutegravir, abacavir, and lamivudine but fewer treatment-related 
adverse events largely due to higher incidence of nausea in the dolutegravir, abacavir, 
lamivudine group.5,6  
We report 144-week outcomes of these two trials to provide data on the relative efficacy and 
safety - including tolerability, renal, bone, and lipid outcomes - of bictegravir, emtricitabine, and 
tenofovir alafenamide versus two different guidelines-recommended, dolutegravir-containing 
regimens in treatment-naïve individuals initiating HIV therapy. 
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Methods 
Study design and procedures 
GS-US-380-1489 and GS-US-380-1490 were both randomised, double-blind, multicentre, 
active-controlled, noninferiority phase 3 trials. Study 1489 was conducted at 122 outpatient 
centres in nine countries Belgium, France, Germany, Italy, Spain, and the United Kingdom, 
Dominican Republic, Canada and the U.S. Study 1490 was conducted at 126 outpatient centres 
in 10 countries including the nine countries above and Australia.  Detailed methods have been 
previously published.5,6 Briefly, Study 1489 investigators enrolled treatment-naïve adults living 
with HIV with plasma HIV-1 RNA levels ≥500 copies per mL who were HLA-B*5701-negative, 
did not have hepatitis B virus, and who had estimated glomerular filtration rate (eGFR) ≥50 mL 
per minute (Cockcroft–Gault equation). Similarly, Study 1490 investigators enrolled treatment-
naïve adults living with HIV with eGFR ≥30 mL per minute; participants with chronic hepatitis B 
infection were permitted to enter. Both studies required virologic resistance testing showing 
sensitivity to emtricitabine and tenofovir. 
These studies were undertaken in accordance with the Declaration of Helsinki and were 
approved by central or site-specific review boards or ethics committees. All participants gave 
written informed consent. 
Randomisation and masking 
Participants were randomised (1:1) to receive a once-daily regimen of coformulated bictegravir 
50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or either dolutegravir 50 mg, 
abacavir 600 mg, and lamivudine 300 mg (Study 1489) or dolutegravir 50 mg, emtricitabine 200 
mg, and tenofovir alafenamide 25 mg (Study 1490). All regimens were given without regard to 
food. Participants also received placebo tablets matching the alternative treatment; thus 
investigators, participants, and study staff giving treatment, assessing outcomes, and collecting 
data were masked to treatment group. A computer-generated allocation sequence (block size 4) 
was created by Bracket (San Francisco, CA, U.S.). Randomisation in each study was stratified 
by HIV-1 RNA (≤100 000 copies per mL, >100 000 to ≤400 000 copies per mL, or >400 000 
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copies per mL), CD4 count (<50 cells per μL, 50 to 199 cells per μL, or ≥200 cells per μL), and 
region (U.S. or ex-U.S.) at screening.  
Procedures 
We conducted post-baseline study visits at weeks 4, 8, 12, and every 12 weeks thereafter, with 
masked treatment visits planned until week 144 as previously reported. Participants were given 
the option of participating in an open-label extension period for an additional 96 weeks (5 years 
of cumulative exposure). Laboratory tests included haematological analysis, serum chemistry 
tests, fasting lipids, CD4 cell counts, measures of renal function (eGFR in both studies; tubular 
proteinuria [urine albumin to creatinine ratio, retinol binding protein to creatinine ratio, β2-
microglobulin to creatinine ratio] in Study 1489 only, (Covance Laboratories, Indianapolis, IN, 
U.S.), and HIV-1 RNA plasma level (Roche TaqMan 2.0; Roche Diagnostics, Rotkreuz, 
Switzerland). Baseline HIV-1 integrase genotyping was conducted by deep sequencing after 
randomization (Seq-IT, Kaiserslautern, Germany). Protocol-defined resistance testing 
(Monogram Biosciences, Inc., South San Francisco, CA, U.S.) was performed for any 
participant who had an HIV-1 RNA ≥50 copies per mL with a confirmed HIV-1 RNA ≥200 copies 
per mL, or who had an HIV-1 RNA ≥200 copies per mL at weeks 48, 96, 144 or the last visit on 
study drug after week 8, and who did not subsequently resuppress HIV-1 RNA while on study 
drug. 
Safety was assessed by physical examinations, laboratory tests, 12-lead electrocardiogram, 
concomitant drugs, and recording of adverse events, which were coded using the Medical 
Dictionary for Regulatory Activities (MedDRA, version 22·0). Relatedness of adverse events to 
blinded study drugs was indicated by the investigator in a binary manner (yes or no). 
In Study 1489, we performed dual energy x-ray absorptiometry (DXA) scans for hip and lumbar 
spine bone mineral density (BMD) before drug administration at baseline and then at weeks 24, 
48, 96 and 144. A centralised centre blinded to treatment group assignment read all scans 
(BioClinica, Newtown, PA, U.S.).  
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Outcomes 
We have previously reported the primary and secondary efficacy outcomes: the proportion of 
participants who had plasma HIV-1 RNA <50 copies per mL at weeks 48 and 965-8 as defined 
by the U.S. Food and Drug Administration (FDA) Snapshot algorithm.9 Another secondary 
efficacy outcome was the proportion of participants who had plasma HIV-1 RNA <50 copies per 
mL by Snapshot algorithm at week 144.  
Sensitivity analyses assessed virologic efficacy at week 144 in pre-specified subgroups of age, 
sex, race, baseline HIV-1 RNA, baseline CD4 cell count, geographic region, and study 
medication adherence. Other secondary efficacy analyses included the proportion of 
participants with plasma HIV-1 RNA <50 copies per mL at week 144 when imputing missing as 
failure (M=F) and missing as excluded (M=E), the proportion of participants with HIV-1 RNA <20 
copies per mL at week 144 by the snapshot algorithm, and change in CD4 cell count from 
baseline at week 144. 
In Study 1489, the percentage changes from baseline in hip and lumbar spine BMD were 
assessed as a secondary outcome at week 144. Renal safety assessments included the 
change from baseline in serum creatinine and eGFR at week 144 (both studies), treatment-
emergent proteinuria through week 144 (both studies), and percentage changes from baseline 
in urine retinol binding protein to creatinine ratio, urine β2-microglobulin to creatinine ratio and 
urine albumin to creatinine ratio at week 144 (Study 1489 only). 
Adverse event incident rates through week 144 and changes in fasting lipids at week 144 were 
assessed by treatment group.  
Statistical analysis 
For each study, we performed the week-144 efficacy analysis (proportion of participants with 
plasma HIV-1 RNA <50 copies per mL at week 144 [between days 967 and 1050, inclusive]) on 
the full analysis set (all participants who were randomised and had received at least one dose of 
the study drug) after enrolled participants had completed their week 144 study visit or had 
prematurely discontinued the study drug. Based on the normal approximation, we assessed 
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noninferiority with a Mantel-Haenszel stratified risk difference and its associated 95% 
confidence interval (CI) in virologic response rates of each study individually (Study 1489: 
bictegravir, emtricitabine, and tenofovir alafenamide minus dolutegravir, abacavir, and 
lamivudine; Study 1490: bictegravir, emtricitabine, and tenofovir alafenamide minus dolutegravir 
plus emtricitabine, and tenofovir alafenamide) with a prespecified noninferiority margin of -12%, 
based on published U.S. FDA regulatory guidance.9 Sample size justification was based on the 
primary outcome.7,8 Statistical analysis followed the methodology previously reported for the 
primary endpoint and included pre-specified subgroups, per-protocol analysis, the proportion of 
participants with plasma HIV RNA <20 copies per mL, and missing as failure (M=F) and missing 
as excluded (M=E) imputations. Changes from baseline in CD4 cell count at week 144 were 
summarised by treatment group with descriptive statistics based on the full analysis set using 
observed on-treatment data. 
Methods for assessing baseline characteristics and safety outcomes including adverse events, 
BMD, renal biomarkers and fasting lipids were also previously reported. Significance testing 
was performed for adverse events with >5% treatment difference using Fisher exact text. A 
post-hoc analysis compared the changes from baseline in weight at week 144 using a two-sided 
Wilcoxon rank sum test. 
We used SAS® Software Version 9·4 (SAS Institute Inc., Cary, NC, U.S.) for all analyses. 
These studies were conducted according to protocol without substantial deviations and are 
registered with ClinicalTrials.gov, numbers NCT02607930 
(https://clinicaltrials.gov/ct2/show/NCT02607930) and NCT02607956 
(https://clinicaltrials.gov/ct2/show/NCT02607956). 
Role of the funding source 
Gilead Sciences funded the study, collected and analysed the data, interpreted the results, and 
helped to write the report. CO, ED, PES, JRA, SKG, CM, JLS, H-JS, DAW, FM, MAT, DP, DH, 
JF, CB, and AC enrolled participants. HM designed the study. HH and RA performed the data 
analyses, which were reviewed and interpreted by DB, SC, and HM. The first draft was written 
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by CO, SC and HM. All authors reviewed and interpreted analyses of data, contributed edits of 
the final report, and approved the draft manuscript. CO and HM made the decision to submit the 
manuscript for publication. 
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Results 
Between November 13, 2015 and July 14, 2016, 631 participants were randomised in Study 
1489 (316 to bictegravir, emtricitabine, and tenofovir alafenamide and 315 to dolutegravir, 
abacavir, and lamivudine) (Figure 1). Of these, 314 received at least one dose of bictegravir, 
emtricitabine, and tenofovir alafenamide and 315 of dolutegravir, abacavir, and lamivudine. 
Between November 11, 2015 and July 15, 2016, 657 participants were randomised in Study 
1490 (327 to bictegravir, emtricitabine, and tenofovir alafenamide and 330 to dolutegravir plus 
emtricitabine and tenofovir alafenamide) (Figure 2). A total of 320 received at least one dose of 
bictegravir, emtricitabine, and tenofovir alafenamide and 325 of dolutegravir plus coformulated 
emtricitabine and tenofovir alafenamide. Demographics and baseline characteristics were 
balanced between the treatment groups in both studies (Table 1). 
At 144 weeks, the fixed-dose combination of bictegravir, emtricitabine, and tenofovir 
alafenamide was noninferior to both dolutegravir-containing regimens as defined by the U.S. 
FDA Snapshot algorithm for the secondary efficacy outcome of the proportion of participants 
with plasma HIV-1 RNA <50 copies per mL (Table 2, Figure 3). 
In Study 1489, 81·5% (256 of 314 participants) who received bictegravir, emtricitabine, and 
tenofovir alafenamide vs 84·1% (265 of 315) who received dolutegravir, abacavir, and 
lamivudine had a plasma HIV-1 RNA <50 copies per mL in the week 144 analysis window 
(difference −2·6%, 95% CI: −8·5% to 3·4%) (Table 2). An HIV-1 RNA ≥50 copies per mL at 
week 144 or at the last test while on study drug was observed in 2 (0·6%) participants in the 
bictegravir, emtricitabine, and tenofovir alafenamide arm and 9 (2·9%) in the dolutegravir, 
abacavir, and lamivudine arm, and there were no discontinuations due to lack of efficacy. A total 
of 17·8% (56 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide arm and 13.0% 
(41 of 315) in the dolutegravir, abacavir, and lamivudine arm did not have data at week 144 but 
their last on-study HIV-1 RNA test was <50 copies per mL. The most common reasons for 
missing data at week 144 were lost to follow-up and participant decision, occurring in 24 (7·6%) 
and 16 (5·1%) in the bictegravir, emtricitabine, and tenofovir alafenamide arm versus 16 (5·1%) 
and 15 (4·8%) dolutegravir, abacavir, and lamivudine arm, respectively. The prespecified per-
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protocol, missing as excluded, and missing as failure analyses were consistent with results from 
the full analysis set showing high overall efficacy and no differences between the treatment 
groups (Table 2). Testing for interactions between treatment and subgroup was performed 
using the Wald test and identified differences between treatment arms favouring dolutegravir, 
abacavir, and lamivudine in the subgroup with cumulative adherence <95% (appendix page 16). 
The difference was driven by subgroup participants who did not have data in the analysis 
window and whose last on treatment assessment of HIV-1 RNA was <50 copies per mL (n=31 
[30·4%] in the bictegravir, emtricitabine, and tenofovir alafenamide arm versus n=15 [12·7%] in 
the dolutegravir, abacavir, and lamivudine arm), rather than virologic failure (appendix page 9). 
No significant treatment differences were noted for other pre-specified subgroups. Results 
across other efficacy outcomes consistently demonstrated the durable efficacy of both regimens 
(Table 2). Six participants with protocol-defined criteria for resistance testing were included in 
the week-144 resistance analysis population; all were in the dolutegravir, abacavir, and 
lamivudine group. Of these, 1 participant had resistance testing between week 96 and 144. No 
emergent resistance developed to any component of either treatment regimen. CD4 cell count 
increased in each treatment group, with mean (SD) changes from baseline at week 144 of 299 
(224·9) cells per μL for bictegravir, emtricitabine, and tenofovir alafenamide and 317 (219·5) 
cells per μL for dolutegravir, abacavir, and lamivudine (p=0·30). 
In Study 1490, 81·9% (262 of 320 participants) who received bictegravir, emtricitabine, and 
tenofovir alafenamide vs 84·0% (273 of 325) who received dolutegravir plus emtricitabine, and 
tenofovir alafenamide had a plasma HIV-1 RNA <50 copies per mL in the week 144 analysis 
window (difference −1·9%, 95% CI: −7·8% to 3·9%) (Table 2). An HIV-1 RNA ≥50 copies per 
mL at week 144 or at the last test while on study drug was observed in 15 (4·7%) in the 
bictegravir, emtricitabine, and tenofovir alafenamide arm and 10 (3·1%) in the dolutegravir plus 
emtricitabine and tenofovir alafenamide arm. The majority of these (14 [4·4%) vs 6 [1·8%]) were 
participants who discontinued study drug due to other reasons not related to efficacy and had a 
last available HIV-1 RNA value ≥50 copies per mL. There were no discontinuations due to lack 
of efficacy. Seven participants from the bictegravir, emtricitabine, and tenofovir alafenamide arm 
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did not have any HIV-1 RNA data after baseline; therefore, the only available HIV-1 RNA, which 
was used to assess efficacy through week 144, was collected before they initiated study 
treatment. We observed no differences between treatment arms in the pre-specified subgroups 
(appendix page 17). Results across other efficacy outcomes consistently demonstrated the 
durable efficacy of both regimens (Table 2). Fifteen participants met criteria for viral resistance 
testing at week 144:  eight in the bictegravir, emtricitabine, and tenofovir alafenamide group and 
seven in the dolutegravir plus emtricitabine and tenofovir alafenamide group. One new 
participant in the bictegravir, emtricitabine, and tenofovir alafenamide group and three 
participants in the dolutegravir plus emtricitabine and tenofovir alafenamide group had 
resistance testing between week 96 and 144. No emergent resistance developed to any 
component of either treatment regimen.  
Baseline HIV-1 integrase genotyping was not required at study entry and was completed 
retrospectively for both studies showing that primary mutations associated with resistance to 
integrase inhibitors were present in 8 (1·3%) participants in Study 1489 and 9 (1·4%) in Study 
1490, all but one of whom had pre-existing Thr97Ala which did not affect virologic outcomes in 
either study. One participant in Study 1489 who had Gln148His + Gly140Ser substitutions with 
phenotypic resistance to raltegravir and elvitegravir, partial resistance to dolutegravir, and full 
sensitivity to bictegravir, was randomised to bictegravir, emtricitabine, and tenofovir alafenamide 
and had HIV-1 RNA <50 copies per mL at week 4 and through week 144. 
In Study 1490, 14 participants had HIV-1 and hepatitis B co-infection at baseline: eight in the 
bictegravir, emtricitabine, and tenofovir alafenamide group and six in the dolutegravir plus 
emtricitabine and tenofovir alafenamide group. At week 144, by M=E analysis 11 of 11 HIV and 
hepatitis B coinfected participants had HBV DNA < 29 IU per mL and HIV-1 RNA <50 copies 
per mL; five of five from the bictegravir, emtricitabine, and tenofovir alafenamide group and six 
of six from the dolutegravir, emtricitabine, and tenofovir alafenamide group. Three participants 
in the bictegravir, emtricitabine, and tenofovir alafenamide had HBV DNA missing at week 144; 
two had no HBV DNA detected at the last visit at which HBV was tested and one had no post-
baseline visits. Among HIV and HBV coinfected participants there were no hepatic adverse 
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events, no grade 3 or 4 adverse events and no participants interrupted or discontinued their 
study regimen due to an adverse event. 
The median study drug exposure was 152 weeks for Study 1489 and 149 weeks in Study 1490. 
Most adverse events were reported as mild or moderate in severity. Table 3 shows adverse 
events reported by 10% or more of participants in any treatment group for each study. In Study 
1489, nausea was reported in significantly fewer participants in the bictegravir, emtricitabine, 
tenofovir alafenamide group than in the dolutegravir, abacavir, and lamivudine group (12% [38 
of 314] vs 24% [76 of 315], p=0·0001). The incidence of nausea was highest after starting 
treatment (week 4: 5% [16 of 314] in the bictegravir, emtricitabine, and tenofovir alafenamide 
group vs 17% [54 of 315] in the dolutegravir, abacavir, and lamivudine group) with a difference 
between treatments in prevalent nausea through week 144 (appendix page 18). In each study, 
adverse events were similar to those reported at weeks 48 and 96. In Study 1489, few 
participants had adverse events that led to study drug discontinuation (0 in the in the bictegravir, 
emtricitabine, and tenofovir alafenamide group vs 2% [5 of 315 participants] in the dolutegravir, 
abacavir, and lamivudine group) (Table 3), all of which occurred before week 96. In Study 1490, 
adverse events leading to study drug discontinuation were also uncommon, occurring in 2% (6 
of 320) of participants in the bictegravir, emtricitabine, and tenofovir alafenamide and 2% (6 of 
325) in the dolutegravir plus emtricitabine and tenofovir alafenamide group (Table 3). Only one 
event (large B-cell lymphoma in the in the dolutegravir plus emtricitabine and tenofovir 
alafenamide group) led to discontinuation between weeks 96 to 144. 
In Study 1489, participants in the bictegravir, emtricitabine, and tenofovir alafenamide group 
had a lower incidence of drug-related adverse events than did those in the dolutegravir, 
abacavir, and lamivudine group (30% [94 of 314] vs 42% [132 of 315], p=0·0021) (Table 3); 
these events were primarily mild or moderate in severity. The difference between groups was 
driven mainly by the significant difference in drug-related nausea reported soon after initiation of 
blinded study drug, which occurred in 6% (18 of 314) bictegravir, emtricitabine, and tenofovir 
alafenamide group vs 18% (56 of 315) dolutegravir, abacavir, and lamivudine group (p<0·0001). 
The study-drug related adverse events reported in ≥2% of participants in Study 1489 are shown 
 
17 
 
on appendix page 10. In Study 1490, study-drug related adverse events were reported for 71 
participants (22%) in the bictegravir, emtricitabine, and tenofovir alafenamide and 95 (29%) in 
the dolutegravir, emtricitabine, and tenofovir alafenamide group. Study-drug related adverse 
events reported in ≥2% of participants in Study 1490 are shown on appendix page 11. In Study 
1490, no single adverse event (MedDRA preferred term) met the 5% threshold for between 
group statistical comparison. No drug-related adverse events of grade 3 or higher were reported 
in >2 participants in either group across both studies. 
In Study 1489, two deaths occurred prior to week 96, as previously reported5,7 (drug overdose 
[n=1] and suicide [n=1] in the bictegravir, emtricitabine, and tenofovir alafenamide group). One 
death (overdose [n=1] in the dolutegravir, abacavir, and lamivudine group) occurred after week 
96. None of the deaths in Study 1489 were considered to be related to treatment. In Study 
1490, eight participants died during the study, four in each group. In the bictegravir, 
emtricitabine, and tenofovir alafenamide group sudden cardiac death was reported in one 
participant after week 96, the other deaths (cardiac arrest following appendicitis and septic 
shock [n=1)] gastric adenocarcinoma [n=1], hypertensive heart disease and congestive cardiac 
failure [n=1]) occurred before week 96, as previously reported.6,8 In the dolutegravir, 
emtricitabine, and tenofovir alafenamide group two deaths occurred after week 96 (unknown 
cause [n=1] and lymphoma [n=1]); the other deaths (unknown cause [n=1] and pulmonary 
embolism [n=1]) occurred prior to week 96, as previously reported.6,8 One death in from 
unknown cause on Study 1490 in a participant on dolutegravir, emtricitabine and tenofovir 
alafenamide was considered possibly related to study treatment, none of the other deaths on 
either study were considered related to study treatment.  
Study drugs were interrupted or discontinued by the investigator when any on-study pregnancy 
was confirmed. Three women in Study 1489 had confirmed pregnancies while on-study, two in 
the bictegravir, emtricitabine, and tenofovir alafenamide group and one in the dolutegravir, 
abacavir, and lamivudine group; all before week 96. The pregnancy outcomes were previously 
reported including a healthy full-term infant (n=1) and spontaneous abortion at 2 weeks 
gestation (n=1) in the bictegravir, emtricitabine, and tenofovir alafenamide group, and elective 
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termination (n=1) in the dolutegravir, abacavir, and lamivudine group. Ten women in Study 1490 
had thirteen confirmed pregnancies, six women in the bictegravir, emtricitabine, and tenofovir 
alafenamide group with nine confirmed pregnancies and four women in the dolutegravir, 
emtricitabine, and tenofovir alafenamide group with four confirmed pregnancies. In the 
bictegravir, emtricitabine, and tenofovir alafenamide group, the pregnancies resulted in 
uncomplicated term delivery (n=3), spontaneous abortion (n=3), elective termination (n=1) and 
two pregnancies are ongoing. In the dolutegravir, emtricitabine, and tenofovir alafenamide 
group, the pregnancies resulted in uncomplicated term delivery (n=3) and elective termination 
(n=1). There were no reports of infant congenital abnormalities in either study.  
The overall laboratory safety profiles at week 144 in both studies were similar to those observed 
at weeks 48 and 96. In Study 1489, grade 3 or 4 laboratory abnormalities were reported for 26% 
(83 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 25% (80 of 
315) in the dolutegravir, abacavir, and lamivudine group (appendix page 12). In Study 1490, 
grade 3 or 4 laboratory abnormalities were reported for 25% (77 of 320) in the bictegravir, 
emtricitabine, and tenofovir alafenamide group and 23% (74 of 325) in the dolutegravir plus 
coformulated emtricitabine and tenofovir alafenamide group (appendix page 13). In both 
studies, incidence and types of abnormalities were generally balanced between treatment 
groups. The majority were transient and resolved on therapy. There were no abnormal 
electrocardiogram findings through week 144 associated with either treatment in each study. 
There were no cases of proximal tubulopathy or Fanconi syndrome reported in either study. No 
study participant who received bictegravir, emtricitabine, and tenofovir alafenamide in either 
study discontinued due to a renal adverse event; one individual in the dolutegravir, abacavir, 
and lamivudine group discontinued treatment in Study 1489 due to renal failure as previously 
reported.5,7 Small increases from baseline in median serum creatinine and decreases in eGFR 
were seen at week 144 for both groups in each study (appendix page 14). At 144 weeks in 
Study 1489, percentage changes in quantitative proteinuria (total urinary albumin to urine 
creatinine ratio) and tubular proteinuria (retinol binding protein and β2-microglobulin to urine 
creatinine ratios) were similar between groups (appendix page 14). 
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In Study 1489, changes from baseline in fasting HDL and triglycerides were similar between 
groups at week 144 (appendix page 15). Significant differences were measured in the median 
changes from baseline in fasting total cholesterol (14 mg/dL vs 10 mg/dL, p=0.034), direct LDL 
(21 mg/dL vs 14 mg/dL, p=0·004), and total cholesterol to HDL ratio (-0.1 vs -0.3, p=0.007) at 
week 144 in the bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, 
abacavir, and lamivudine groups. There were no differences between groups in initiation of lipid-
modifying agents during the study for the bictegravir, emtricitabine and tenofovir alafenamide 
compared to dolutegravir, abacavir, and lamivudine groups through week 144: 5% (16 of 314) 
vs 5% (16 of 315) (p=1·00). No differences in median changes from baseline in fasting lipid 
parameters at week 144 were noted for the bictegravir, emtricitabine and tenofovir alafenamide 
and dolutegravir, emtricitabine and tenofovir alafenamide groups in Study 1490 (appendix page 
15). 
There were small changes from baseline in hip and lumbar spine BMD that were similar 
between the bictegravir, emtricitabine, and tenofovir alafenamide and dolutegravir, abacavir, 
and lamivudine groups in Study 1489. Mean percentage changes at week 144 were -1·02% 
vs -1·29% (p=0·39 for difference in percentage changes at week 144 between groups) at the 
hip and -0·37% vs +0·04% at lumbar spine (p=0·26) (Figure 4). There were similar changes 
from baseline in weight at week 144 in both groups in each study (appendix pages 15 and 19). 
In Study 1489, the median change in weight from baseline (interquartile range) was +4·1 kg 
(0·3, 8·7) in the bictegravir, emtricitabine, and tenofovir alafenamide group and +3·5 kg (0·0, 
7·7) in the dolutegravir, abacavir, and lamivudine group (P=0.196). In Study 1490, the median 
change (interquartile range) was +4·4 kg (1·0, 9·0) in the bictegravir, emtricitabine, and 
tenofovir alafenamide group and +5·0 kg (0·5, 9·7) in the dolutegravir plus emtricitabine and 
tenofovir alafenamide group (P=0.649). 
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Discussion 
Current results from these two large, randomised, phase 3 trials offer three-year data 
demonstrating noninferiority of coformulated bictegravir, emtricitabine, and tenofovir 
alafenamide to two dolutegravir-containing regimens for initial treatment of people with HIV. The 
proportions who remained virologically suppressed at 144 weeks were high, with similar efficacy 
for participants with high baseline plasma HIV-1 RNA (>100,000 copies per mL) and for those 
with CD4 cell counts above and below 200 cells per uL. Virologic failure was rare; no participant 
in either study discontinued due to a lack of efficacy and very few had plasma HIV-1 RNA 
>50 copies per mL at week 144. Notably, no participant in either trial had emergent drug 
resistance detected. 
Few discontinuations of study drug due to intolerance or adverse effects were reported through 
144 weeks (six of 634 participants [1%] on bictegravir, emtricitabine, and tenofovir alafenamide 
across both studies, five of 315 (2%) on dolutegravir, abacavir, and lamivudine, and six of 325 
(2%) on dolutegravir plus emtricitabine and tenofovir alafenamide). In Study 1489, more 
participants (24%) treated with dolutegravir, abacavir, and lamivudine experienced nausea 
compared to those (12%) treated with bictegravir, emtricitabine, and tenofovir alafenamide. 
Though nausea most commonly occurred shortly after starting treatment, prevalence remained 
higher in the dolutegravir, abacavir, and lamivudine group throughout the three-year study 
period. 
In 144 weeks of follow-up in these two large clinical trials, there were no participants who had 
treatment-emergent resistance detected, which underscores the high barrier to resistance for 
standard-of-care regimens containing either bictegravir or dolutegravir in combination with two 
NRTIs. A lack of emergent drug resistance is essential to the lifelong durability of HIV treatment.  
Across both studies, no participant was diagnosed with proximal tubulopathy or Fanconi 
syndrome. As expected, given the inhibition of renal creatinine transporters by both bictegravir 
and dolutegravir, there were small increases from baseline in serum creatinine that occurred 
early. Estimated glomerular filtration remained stable in the treatment groups from week 4 
through week 144 and did not show evidence of renal toxicity with longer exposure to the 
 
21 
 
treatment regimens. Similarly, in Study 1489 which included longitudinal monitoring of bone 
density using dual-energy x-ray absorptiometry, there were no differences in bone mineral 
density changes between bictegravir, emtricitabine, and tenofovir alafenamide and dolutegravir, 
abacavir, and lamivudine groups. Both treatments showed similar, well-described declines after 
antiretroviral treatment was started, reaching a nadir at week 24 for the spine before increasing 
towards baseline and a plateau after week 48 for measurements at the hip.  
Lipids changed from baseline in all groups. Participants in Study 1489 receiving bictegravir, 
emtricitabine, and tenofovir alafenamide had modestly larger increases in total and direct LDL 
cholesterol, as well as smaller reductions in total cholesterol:HDL ratio, than those receiving 
dolutegravir, abacavir, and lamivudine. 
Consistent with data from prior studies in treatment-naïve populations,11-16 participants in both 
studies experienced  weight gain. Interestingly, statistically significant differences in change in 
weight from baseline between the treatment groups were not observed in either study at week 
144. Weight gain and obesity related morbidity and mortality among people with HIV is 
increasingly recognized as an emerging concern  and has been associated with antiretroviral 
drugs and patient characteristics 11, 17-22.  
Consistent with other data, a pooled analysis, which included data from Studies 1489 and 1490, 
showed that newer antiretroviral agents, including bictegravir, dolutegravir and tenofovir 
alafenamide used in this study, were consistently associated with more weight gain than older 
comparators and speculated that improved tolerability of treatments may be a contributing factor 
to differential weight gain over time.11 The metabolic implications of the weight gain and lipid 
changes observed in these studies are unknown and warrant further study. Biological 
mechanisms that may contribute to differential weight gain on antiretroviral therapy are yet to be 
determined. 
These studies have several limitations. Importantly, the relatively low enrolment of women and 
people with advanced HIV disease mean that the findings cannot be assumed to be 
generalizable to these populations. Given the lack of data supporting the use of bictegravir, 
emtricitabine and tenofovir alafenamide in pregnant women, we restricted enrolment only to 
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women of childbearing potential who were willing to conform to the protocol’s stringent birth 
control requirements. An international study of 470 women with suppressed plasma HIV-1 RNA 
showed high rates of continued suppression after switching to bictegravir, emtricitabine, and 
tenofovir alafenamide with no discontinuations due to adverse events.23 Although our results are 
similar, they are based on too small a sample of women to be considered definitive supportive 
of this finding. Given the known increased risk for weight gain in women and people with 
advanced HIV disease who start antiretroviral therapy, a greater degree of weight gain may be 
expected in a cohort with higher percentages of women and people with advanced HIV. In a 
pooled analysis of week 144 results for Studies 1489 and 1490, the median changes in weight 
for women were 5.0 kg in the bictegravir, emtricitabine, and tenofovir alafenamide group, 7.9 kg 
in the dolutegravir, abacavir, and lamivudine group, and 4.9 kg in the dolutegravir, emtricitabine 
tenofovir alafenamide group.24 
Overall, these results demonstrate that all three regimens were efficacious and safe. In 
distinguishing among them, the higher rates of study-drug related adverse events and the 
limitations to the use of dolutegravir, abacavir, and lamivudine, including among those with 
hepatitis B virus co-infection and the requirement for HLA-B*5701 screening, support the use of 
bictegravir, emtricitabine, and tenofovir alafenamide, or alternatively dolutegravir plus 
emtricitabine, tenofovir alafenamide in particular patient populations.  
In summary, as was observed at weeks 48 and 96, bictegravir, emtricitabine, and tenofovir 
alafenamide at 144 weeks of therapy continued to be noninferior to dolutegravir-containing 
regimens, with no emergent drug resistance or proximal renal tubulopathy detected, but with a 
better gastrointestinal tolerability profile. Further open-label follow-up through a total of 5 years 
of exposure in each study will provide further information about the safety and durable efficacy 
of bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV. 
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Table 1. Baseline demographic and clinical characteristics 
Characteristic 
Study 1489 Study 1490 
Bictegravir, emtricitabine, 
and tenofovir alafenamide 
(n=314) 
Dolutegravir, abacavir,  
and lamivudine 
(n=315) 
Bictegravir, emtricitabine, 
and tenofovir alafenamide  
(n=320) 
Dolutegravir plus emtricitabine, 
and tenofovir alafenamide 
(n=325) 
Age (years) 31 (18, 71) 32 (18, 68) 33 (18, 71) 34 (18, 77) 
Women 29 (9%) 33 (10%) 40 (13%) 37 (11%) 
Race     
White 180 (58%) 179 (57%) 183 (57%) 195 (60%) 
Black 114 (36%) 112 (36%) 97 (30%) 100 (31%) 
Asian 6 (2%) 10 (3%) 7 (2%) 10 (3%) 
Ethnicity     
Hispanic or Latino 72 (23%) 65 (21%) 83 (26%) 81 (25%) 
HIV Disease status     
Asymptomatic 286 (91%) 286 (91%) 286 (89%) 288 (89%) 
Symptomatic 16 (5%) 14 (4%) 10 (3%) 11 (3%) 
AIDS 12 (4%) 15 (5%) 24 (8%) 26 (8%) 
HIV risk factor     
Heterosexual sex 61 (19%) 62 (20%) 81 (25%) 77 (24%) 
Homosexual sex 251 (80%) 250 (79%) 237 (74%) 250 (77%) 
Intravenous drug use 5 (2%) 4 (1%) 3 (1%) 6 (2%) 
HIV-1 RNA log10 copies per mL 4.42 (4.03, 4.87) 4.51 (4.04, 4.87) 4.43 (3.95, 4.90) 4.45 (4.03, 4.84) 
HIV-1 RNA concentration  
>100 000 copies per mL 
53 (17%) 50 (16%) 66 (21%) 54 (17%) 
CD4 count (cells per μL) 443 (299, 590) 450 (324, 608) 440 (289, 591) 441 (297, 597) 
Number with CD4 cell count  
(cells per μL) 
    
<200 36 (11%) 32 (10%) 44 (14%) 34 (10%) 
≥200 to <500 156 (50%) 149 (47%) 158 (49%) 171 (53%) 
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Characteristic 
Study 1489 Study 1490 
Bictegravir, emtricitabine, 
and tenofovir alafenamide 
(n=314) 
Dolutegravir, abacavir,  
and lamivudine 
(n=315) 
Bictegravir, emtricitabine, 
and tenofovir alafenamide  
(n=320) 
Dolutegravir plus emtricitabine, 
and tenofovir alafenamide 
(n=325) 
≥500 122 (39%) 134 (43%) 118 (37%) 120 (37%) 
Creatinine clearance by Cockcroft-
Gault formula (mL/min) 
125.9 (107.7, 146.3) 123.0 (107.0, 144.3) 120.4 (100.8, 141.8) 120.6 (102.8, 145.1) 
Body-mass index (kg/m2) 25.1 (22.4, 28.7) 24.9 (22.5, 29.1) 25.0 (22.2, 28.3) 24.6 (22.2, 28.0) 
Primary resistance-associated 
mutationsb 
    
INSTI  4 (1.3%) 4 (1.3%) 3 (1%) 6 (2%) 
NRTI 6 (1.9%) 5 (1.6%) 10 (3%) 5 (2%) 
NNRTI 36 (11.5%) 51 (16.2%) 41 (13%) 41 (13%) 
PI 12 (3.8%) 11 (3.5%) 4 (1%) 10 (3%) 
HIV/HBV Coinfected   8 (3%)  6 (2%) 
HIV/HCV Coinfected   5 (2%)  5 (2%) 
Data are median (IQR) or n (%), except for age, which is median (range). 
INSTI = integrase strand transfer inhibitor; IQR, interquartile range; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside/tide reverse transcriptase inhibitor; PI = protease inhibitor 
a A participant may fit more than one HIV risk factor category; therefore, percentages may add to more than 100%. 
b Primary INSTI substitutions are Thr66Ala/Ile/Lys, Glu92Gly/Gln, Thr97Ala, Phe121Tyr, Tyr143Cys/His/Arg, Ser147Gly, Gln148His/Lys/Arg, Asn155His/Ser, Arg263Lys in IN. Primary NRTI substitutions 
are Met41Leu, Lys65Glu/Asn/Arg, Asp67Asn, Thr69 insertions, Lys70Glu/Arg, Leu74Ile/Val, Tyr115Phe, Gln151Met, Met184Val/Ile, Leu210Trp, Thr215Tyr/Phe, Lys219Glu/Asn/Gln/Arg in RT. Primary 
NNRTI substitutions are Leu100Ile, Lys101Glu/Pro, Lys103Asn/Ser, Val106Ala/Met, Val108Ile, Glu138Ala/Gly/Lys/Gln/Arg, Val179Leu, Tyr181Cys/Ile/Val, Tyr188Cys/Leu/His, Gly190Ala/Glu/Gln/Ser, 
His221Tyr, Pro225His, Phe227Cys, Met230Ile/Leu in RT. Primary PI substitutions are Asp30Asn, Val32Ile, Met46Ile/Leu, Ile47Ala/Val, Gly48Val, Ile50Val/Leu, Ile54Leu/Met, Gln58Glu, Thr74Pro, 
Leu76Val, Val82Ala/Phe/Leu/Thr/Ser, Asn83Asp, Ile84Val, Asn88Ser, Leu90Met in PR. 
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Table 2. Virologic outcomes at week 144 
 
Study 1489 Study 1490 
Bictegravir, emtricitabine, 
and tenofovir alafenamide 
(n=314) 
Dolutegravir, abacavir,  
and lamivudine 
(n=315) 
Bictegravir, emtricitabine, 
and tenofovir alafenamide  
(n=320) 
Dolutegravir plus 
emtricitabine, and tenofovir 
alafenamide 
(n=325) 
HIV-1 RNA <50 copies per mL (full analysis set) 256 (81.5%) 265 (84.1%) 262 (81.9%) 273 (84.0%) 
Difference in Percentages (95% CI)† -2.6% (-8.5% to 3.4%) -1.9% (-7.8% to 3.9%) 
HIV-1 RNA ≥50 copies per mL 2 (0.6%) 9 (2.9%) 15 (4.7%) 10 (3.1%) 
HIV-1 RNA ≥50 copies per mL 1 (0.3%) 2 (0.6%) 1 (0.3%) 4 (1.2%) 
Discontinued Due to Lack of Efficacy 0 0 0 0 
Discontinued Due to Other Reasons* and 
Last Available HIV-1 RNA ≥50 copies per mL 
1 (0.3%) 7 (0.6%) 14 (4.4%) 6 (1.8%) 
No Virologic Data 56 (17.8%) 41 (13.0%) 43 (13.4%) 42 (12.9%) 
Discontinued Due to AE/Death¥ 2 (0.6%) 6 (1.9%) 8 (2.5%) 9 (2.8%) 
Discontinued Due to Other Reasons* and 
Last Available HIV-1 RNA <50 copies per mL 
50 (15.9%) 34 (10.8%) 35 (10.9%) 29 (8.9%) 
Missing Data but on Study Drug 4 (1.3%) 1 (0.3%) 0 4 (1.2%) 
HIV-1 RNA <50 copies per mL (per-protocol set) 256/257 (99.6%) 260/262 (99.2%) 257/258 (99.6%) 270/273 (98.9%) 
Difference in Percentages (95% CI)† 0.4% (-1.6% to 2.4%) 0.7% (-1.4% to 2.7%) 
HIV-1 RNA <50 copies per mL by 
Missing = Failure 
259/314 (82.5%) 267/315 (84.8%) 268/320 (83.8%) 276/325 (84.9%) 
Difference in Percentages (95% CI)** -2.3% (-8.1% to 3.6%) -0.9% (-6.6% to 4.7%) 
HIV-1 RNA <50 copies per mL by 
Missing = Excluded 
259/260 (99.6%) 267/269 (99.3%) 268/270 (99.3%) 276/280 (98.6%) 
Difference in Percentages (95% CI)** 0.4% (-1.6% to 2.3%) 0.7% (-1.6% to 2.9%) 
HIV-1 RNA <20 copies per mL (full analysis set) 245 (78.0%) 259 (82.2%) 248 (77.5%) 257 (79.1%) 
Difference in Percentages (95% CI)† -4.2% (-10.5% to 2.1%) -1.1% (-7.4% to 5.3%) 
Data are n (%). 
The Week 144 window is between Days 967 and 1050 (inclusive). 
*Other reasons include subjects who discontinued study drug due to investigator’s discretion, subject decision, lost to follow-up, noncompliance with study drug, protocol violation, pregnancy, and study 
terminated by sponsor. 
† The difference in percentages of subjects with HIV-1 RNA < 50 copies/mL between treatment groups and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA 
stratum and region stratum¥ One death in the bictegravir, emtricitabine, and tenofovir alafenamide occurred after the participant reached the week 96 outcome. 
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** Difference in percentages, and 95% CI were based on a dichotomized response: HIV-1 RNA <50 copies/mL vs. HIV-1 RNA ≥ 50 copies/mL or missing for missing = failure approach and HIV-1 RNA 
<50 copies/mL vs. HIV-1 RNA ≥ 50 copies/mL for missing = excluded approach. Difference in percentages of subjects with HIV-1 RNA < 50 copies/mL between treatment groups and its 95% CI 
were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum and region stratum.  
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Table 3. Adverse events through week 144 
 
Study 1489 Study 1490 
Bictegravir, 
emtricitabine, and 
tenofovir alafenamide 
(n=314) 
Dolutegravir, 
abacavir,  
and lamivudine 
(n=315) p-value¥ 
Bictegravir, 
emtricitabine, and 
tenofovir alafenamide  
(n=320) 
Dolutegravir plus 
emtricitabine, and 
tenofovir alafenamide 
(n=325) p-value¥ 
Any adverse event 300 (95.5%)  304 (96.5%) ─ 291 (90.9%) 3 300 (92.3%) ─ 
Adverse event ≥10%       
 Nausea 38 (12.1%) 76 (24.1%) 0.0001 31 (9.7%)  42 (12.9%) ─ 
 Diarrhoea 54 (17.2%)  57 (18.1%) ─ 66 (20.6%)  52 (16.0%) ─ 
 Upper respiratory tract infection 43 (13.7%) 59 (18.7%) ─ 43 (13.4%)  52 (16.0%) ─ 
 Headache 44 (14.0%)  56 (17.8%) ─ 56 (17.5%)  57 (17.5%) ─ 
 Nasopharyngitis 40 (12.7%)  52 (16.5%) ─ 50 (15.6%)  62 (19.1%) ─ 
 Syphilis 39 (12.4%)  49 (15.6%) ─ 33 (10.3%)  31 (9.5%) ─ 
 Back pain 34 (10.8%)  38 (12.1%) ─ 28 (8.8%)  38 (11.7%) ─ 
 Fatigue 33 (10.5%)) 38 (12.1% ─ 28 (8.8%)  36 (11.1%) ─ 
 Insomnia 25 (8.0%) 35 (11.1%) ─ 29 (9.1%)  24 (7.4%) ─ 
 Oropharyngeal pain 21 (6.7%)  35 (11.1%) ─ 20 (6.3%)  18 (5.5%) ─ 
 Cough 34 (10.8%)  20 (6.3%) ─ 25 (7.8%)  29 (8.9%) ─ 
Grade 3 or 4 adverse event 50 (15.9%)  50 (15.9%) ─ 54 (16.9%)  43 (13.2%) ─ 
Serious adverse event 41 (13.1%)  53 (16.8%) ─ 63 (19.7%)  40 (12.3%) ─ 
Study drug-related adverse event 94 (29.9%)  132 (41.9%) 0.0021 71 (22.2%)  95 (29.2%) ─ 
Study drug-related adverse event ≥5%       
Nausea 18 (5.7%)  56 (17.8%) <0.0001 10 (3.1%)  17 (5.2%) ─ 
Diarrhoea 19 (6.1%)  13 (4.1%) ─ 10 (3.1%)  10 (3.1%) ─ 
Headache 16 (5.1%)  16 (5.1%) ─ 14 (4.4%)  10 (3.1%) ─ 
Study drug-related serious adverse event 2 (0.6%)  1 (0.3%) ─ 3 (0.9%)  3 (0.9%) ─ 
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Study 1489 Study 1490 
Bictegravir, 
emtricitabine, and 
tenofovir alafenamide 
(n=314) 
Dolutegravir, 
abacavir,  
and lamivudine 
(n=315) p-value¥ 
Bictegravir, 
emtricitabine, and 
tenofovir alafenamide  
(n=320) 
Dolutegravir plus 
emtricitabine, and 
tenofovir alafenamide 
(n=325) p-value¥ 
Any adverse event leading to study drug 
discontinuation* 
0 5 (1.6%) 
─ 6 (1.9%)  6 (1.8%) ─ 
Death† 2 (0.6%)  1 (0.3%) ─ 4 (1.3%)  4 (1.2%) ─ 
Data are n (%). 
¥ Significance testing was performed for events with >5% treatment difference. P-values were calculated using Fisher exact text. 
* In Study 1489, adverse event-related study drug discontinuations in the dolutegravir, abacavir, and lamivudine group included nausea and rash generalized (day 4, n=1); thrombocytopenia (day 50, 
n=1); chronic pancreatitis and steatorrhoea (day 134, n=1); depression (day 248, n=1); and renal failure (day 621, n=1). 
† In Study 1489, deaths in the bictegravir, emtricitabine, and tenofovir alafenamide group included recreational drug overdose (day 771, n=1) and suicide (day 656, n=1); neither event was considered to 
be treatment related. The death in the dolutegravir, abacavir, and lamivudine group was recreational drug overdose (day 812, n=1); this event was not considered to be treatment related. In Study 
1490, deaths in the bictegravir, emtricitabine, and tenofovir alafenamide group included cardiac arrest following appendicitis and septic shock (day 28, n=1), gastric adenocarcinoma (day 376, n=1), 
hypertensive heart disease and congestive heart failure (Day 412, n=1), and sudden cardiac death (day 1060, n=1). Deaths in the dolutegravir plus emtricitabine and tenofovir alafenamide group 
included unknown causes (day 174, n=1; day 771, n=1), pulmonary embolism (day 266, n=1), and lymphoma (day 422, n=1). None of the deaths in either study were considered to be treatment 
related. 
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Figure 1. Study 1489: study profile through week 144 
739 participants screened
316 randomised to bictegravir, 
emtricitabine, and tenofovir alafenimide
315 randomised to abacavir, 
dolutegravir, and lamivudine 
2 never treated
314 randomly assigned/treated
with bictegravir, emtricitabine, and 
tenofovir alafenamide
315 randomly assigned/treated
with and abacavir, dolutegravir, and 
llamivudine
54 discontinued
     2 died     
     1 had a pregnancy
     6 at Investigator’s discretion
     3 had non-compliance with study drugs
     2 had a protocol violation
     16 at participant’s decision
     24 were lost to follow-up
48 discontinued
     1 died
     5 had an adverse event
     2 at Investigator’s discretion
     6 had non-compliance with study drugs
     3 had a protocol violation
     15 at participant’s decision
     16 were lost to follow-up
108 not randomised
     89 did not meet eligibility criteria
     8 lost to follow-up
     6 withdrew consent
     2 investigator decision
     1 outside visit window
     1 adverse event
     1 other
631 participants randomised
260 continued on treatment 267 continued on treatment
 
 
AE, adverse event; B/F/TAF, bictegravir, emtricitabine, and tenofovir alafenamide; D/C, discontinuation; DTG/ABC/3TC, dolutegravir, abacavir, 
lamivudine 
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Figure 2. Study 1490: study profile through week 144 
742 participants assessed 
for eligibility
327 assigned to  bictegravir, 
emtricitabine, and tenofovir alafenamide
330 randomised to dolutegravir plus 
emtricitabine, and tenofovir alafenamide 
7 never treated
320 received treatment 325 received treatment
59 discontinued treatment
     6 had an adverse event†    
     3 died     
     5 had a pregnancy
     6 at Investigator’s discretion
     3 had a protocol violation
     18 at participant’s decision
     18 were lost to follow-up
47 discontinued
     6 had an adverse event
     4 died
     3 had a pregnancy
     2 at Investigator’s discretion
     4 had non-compliance with study drugs
     1 had a protocol violation
     13 at participant’s decision
     14 were lost to follow-up
261 continued on treatment 278 continued on treatment
85 not randomised
     60 did not meet eligibility criteria
     14 withdrew consent
     3 lost to follow-up
     2 investigator decision
     2 outside visit window
     1 adverse event
     3 other
657 participants enrolled and 
randomised
5 never treated
 
 
No participants discontinued treatment due to reasons related to efficacy. *One participant who discontinued because of an adverse event had a 
cardiac arrest (following appendicitis and septic shock) and died. 
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Figure 3. Virologic outcome at week 144 
A) Study 1489 
 
 
 
B) Study 1490 
 
 
 
% treatment difference was adjusted for both studies. 
 
B/F/TAF, bictegravir, emtricitabine, and tenofovir alafenamide; CI, confidence interval; DTG/ABC/3TC, dolutegravir, 
abacavir, lamivudine; FAS, full analysis set 
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Figure 4. Mean (95% CI) percent change from baseline at weeks 24, 48, 96, and 144 in lumbar 
spine and hip BMD by DXA (Study 1489) 
 
 
 
B/F/TAF = bictegravir, emtricitabine, and tenofovir alafenamide 
DTG/ABC/3TC = dolutegravir, abacavir, and lamivudine 
BMD = bone mineral density 
Bars show 95% CI. 
 
 
 
